Since pyruvate could not significantly reduce most of the obesity-induced metabolic dysregulation, this features the concept that the mechanism of pyruvate primarily revolves around the maintenance of healthy body weight, thereby mitigating downstream effects rather than directly impacting variations in glucose tolerance or dyslipidemia etc. In a way, it further validated our results that cPLA2 is a molecular target of pyruvate. Here, PLA2G4A is linked to obesity disorder.